Redhill Biopharma Ltd
RDHL1.195USD
-0.005-0.42%
取引時間 （ET）15分遅れの株価
1.54M時価総額
0.13直近12ヶ月PER
詳細情報 Redhill Biopharma Ltd 企業名
RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.
企業情報
企業コードRDHL
会社名Redhill Biopharma Ltd
上場日Feb 01, 2011
最高経営責任者「CEO」Mr. Dror Ben-Asher
従業員数35
証券種類Depository Receipt
決算期末Feb 01
本社所在地21 Ha'arba'a St.
都市TEL AVIV-YAFO
証券取引所NASDAQ Capital Market Consolidated
国Israel
郵便番号6473921
電話番号97235413131
ウェブサイトhttps://www.redhillbio.com/
企業コードRDHL
上場日Feb 01, 2011
最高経営責任者「CEO」Mr. Dror Ben-Asher
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Shmuel Cabilly, Ph.D.
Dr. Shmuel Cabilly, Ph.D.
Independent Director
Independent Director
--
--
Ms. Patricia Anderson
Ms. Patricia Anderson
Senior Vice President - Regulatory Affairs
Senior Vice President - Regulatory Affairs
--
--
Mr. Razi Ingber
Mr. Razi Ingber
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Alexandra Okmian
Mr. Alexandra Okmian
Investor Relations
Investor Relations
--
--
Mr. Adi Frish
Mr. Adi Frish
Chief Corporate and Business Development Officer
Chief Corporate and Business Development Officer
--
--
Mr. Dror Ben-Asher
Mr. Dror Ben-Asher
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Reza Fathi, Ph.D.
Dr. Reza Fathi, Ph.D.
Senior Vice President - Research and Development
Senior Vice President - Research and Development
--
--
Mr. Ofer Tsimchi
Mr. Ofer Tsimchi
Independent Director
Independent Director
--
--
Dr. Kenneth Reed, M.D.
Dr. Kenneth Reed, M.D.
Independent Director
Independent Director
--
--
Mr. Guy Goldberg, J.D.
Mr. Guy Goldberg, J.D.
Chief Business Officer
Chief Business Officer
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Shmuel Cabilly, Ph.D.
Dr. Shmuel Cabilly, Ph.D.
Independent Director
Independent Director
--
--
Ms. Patricia Anderson
Ms. Patricia Anderson
Senior Vice President - Regulatory Affairs
Senior Vice President - Regulatory Affairs
--
--
Mr. Razi Ingber
Mr. Razi Ingber
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Alexandra Okmian
Mr. Alexandra Okmian
Investor Relations
Investor Relations
--
--
Mr. Adi Frish
Mr. Adi Frish
Chief Corporate and Business Development Officer
Chief Corporate and Business Development Officer
--
--
Mr. Dror Ben-Asher
Mr. Dror Ben-Asher
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
収益内訳
データなし
データなし
事業別
地域別
データなし
株主
更新時刻: Wed, Jul 2
更新時刻: Wed, Jul 2
株主統計
種類
株主統計
株主統計
比率
Heights Capital Management, Inc.
3.05%
Citadel Advisors LLC
0.94%
Desjardins Securities Inc.
0.15%
GAMMA Investing LLC
0.09%
Rhumbline Advisers Ltd. Partnership
0.06%
Other
95.72%
株主統計
株主統計
比率
Heights Capital Management, Inc.
3.05%
Citadel Advisors LLC
0.94%
Desjardins Securities Inc.
0.15%
GAMMA Investing LLC
0.09%
Rhumbline Advisers Ltd. Partnership
0.06%
Other
95.72%
種類
株主統計
比率
Investment Advisor
3.11%
Hedge Fund
0.94%
Research Firm
0.16%
Investment Advisor/Hedge Fund
0.09%
Other
95.70%
機関投資家保有株
更新時刻: Tue, Jul 1
更新時刻: Tue, Jul 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q2
39
98.72K
4.30%
-26.30K
2025Q1
45
100.27K
5.67%
-27.27K
2024Q4
61
86.70K
6.77%
-35.73K
2024Q3
77
75.64K
5.91%
-52.57K
2024Q2
82
147.72K
11.56%
-10.64K
2024Q1
84
175.94K
13.78%
+109.25K
2023Q4
94
19.30K
14.67%
-65.78K
2023Q3
106
74.17K
44.30%
+53.53K
2023Q2
113
26.79K
29.96%
+840.00
2023Q1
122
24.63K
29.02%
+7.31K
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Heights Capital Management, Inc.
70.00K
3.05%
+70.00K
--
Jan 25, 2024
Citadel Advisors LLC
21.51K
0.94%
+21.51K
--
Mar 31, 2025
Desjardins Securities Inc.
3.39K
0.15%
--
--
Mar 31, 2025
GAMMA Investing LLC
3.57K
0.16%
-1.52K
-29.89%
Mar 31, 2025
Rhumbline Advisers Ltd. Partnership
1.39K
0.06%
+190.00
+15.86%
Mar 31, 2025
BofA Global Research (US)
303.00
0.01%
+301.00
+15050.00%
Mar 31, 2025
Group One Trading, L.P.
22.00
0%
--
--
Mar 31, 2025
Yorkville Asset Management, Inc.
14.00
0%
--
--
Sep 30, 2024
Morgan Stanley & Co. LLC
11.00
0%
-2.20K
-99.50%
Mar 31, 2025
FMP Wealth Advisers
47.00
0%
+47.00
--
Mar 31, 2025
詳細を見る
関連ETF
銘柄名
比率
データなし
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
Aug 06, 2024
Merger
25<1
Aug 06, 2024
Merger
25<1
Aug 06, 2024
Merger
25<1
Aug 06, 2024
Merger
25<1
Mar 17, 2023
Merger
40<1
Mar 17, 2023
Merger
40<1
日付
種類
比率
Aug 06, 2024
Merger
25<1
Aug 06, 2024
Merger
25<1
Aug 06, 2024
Merger
25<1
Aug 06, 2024
Merger
25<1
Mar 17, 2023
Merger
40<1
Mar 17, 2023
Merger
40<1
Mar 17, 2023
Merger
40<1
Mar 17, 2023
Merger
40<1
